insights_auto
Why is GIFLF down 5,24%?
Dive Deeperchevron_right
GIFLF:OTCMKTS
Grifols SA Class A
10,55 $
arrow_downward
-5,24%(-0,58) 1D
13 հոկ, 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GIFLF...
Open
10,55 $
High
10,55 $
Low
10,55 $
Mkt. cap
6,58 մլրդ
Avg. vol.
543,00
Volume
9,70 հզր
52-wk high
12,90 $
52-wk low
10,13 $
Beta
0,90
Shares outstanding
426,13 մլն
No. of employees
25 հզր
Open
10,55 $
High
10,55 $
Low
10,55 $
Mkt. cap
6,58 մլրդ
Avg. vol.
543,00
Volume
9,70 հզր
52-wk high
12,90 $
52-wk low
10,13 $
Beta
0,90
Shares outstanding
426,13 մլն
No. of employees
25 հզր
News stories
From web sources and news partners
ad-hoc-news.de
·
14 ժամ առաջ
Wall Street Zen downgrades Grifols stock from Buy to Hold
ad-hoc-news.de
·
1 օր առաջ
Grifols stock trades at EUR 10.03 with EUR 6.8 billion market value
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA Class A